Company Profiles

driven by the PitchBook Platform

Aerpio Therapeutics

Description

Developer of novel therapies designed to treat vascular disorders. The company develops diabetic retinopathy (DR) and a hypoxia-inducible factor α (HIF-α) stabilizer for the treatment of inflammatory bowel disease providing the treatment for diabetic eye disease without repeated injections into the eye.

2011

Founded

PUBLIC

Status

1-10

Employees

PIPE

Latest Deal Type

$40M

Latest Deal Amount

$71M

Total Amount Raised

Description

Developer of novel therapies designed to treat vascular disorders. The company develops diabetic retinopathy (DR) and a hypoxia-inducible factor α (HIF-α) stabilizer for the treatment of inflammatory bowel disease providing the treatment for diabetic eye disease without repeated injections into the eye.

Website:

www.aerpio.com

Ownership Status

Publicly held

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Biotechnology

Primary Office

9987 Carver Road Suite 420 Cincinnati, OH 45242United States +1 (513) 985-1920
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Aerpio Therapeutics's full profile, request a free trial.

Aerpio Therapeutics Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Aerpio Therapeutics Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

Aerpio Therapeutics Investors (13)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
Ally Bridge GroupVenture CapitalMinority000 0000000 0000
Athenian Venture PartnersVenture CapitalMinority000 0000000 0000
CincyTechVenture CapitalMinority000 0000000 0000
GeneChem ManagementVenture CapitalMinority000 0000000 0000
Kearny Venture PartnersVenture CapitalMinority000 0000000 0000
Ally Bridge Group Venture Capital
Athenian Venture Partners Venture Capital
CincyTech Venture Capital
GeneChem Management Venture Capital
Kearny Venture Partners Venture Capital

Aerpio Therapeutics Executive Team (6)

NameTitleBoard
Seat
Contact
Info
Joseph Gardner Ph.DChief Executive Officer, President & Board Member
Kevin PetersChief Scientific Officer
Sally GravesController
Mitchell Brigell Ph.DVice President of Clinical Development and VP and Director of Clinical Sciences, Ophthalmology
Dhaval DesaiVice President, Medical Affairs
Joseph Gardner Ph.D Chief Executive Officer, President & Board Member
Kevin Peters Chief Scientific Officer
Sally Graves Controller
Mitchell Brigell Ph.D Vice President of Clinical Development and VP and Director of Clinical Sciences, Ophthalmology
Dhaval Desai Vice President, Medical Affairs

Aerpio Therapeutics Board Members (15)

NameRepresentingRoleSinceContact
Info
Adrienne Graves Ph.DSelfBoard of Directors000 0000
Anupam Dalal MDKearny Venture PartnersManaging Director000 0000
Caley Castelein MDKearny Venture PartnersPartner, Managing Member & Founder000 0000
Campbell Murray MDNovartis Venture FundManaging Director000 0000
Chau KhuongOrbiMedPrivate Equity Partner000 0000
Adrienne Graves Ph.D Board of Directors Self
Anupam Dalal MD Managing Director Kearny Venture Partners
Caley Castelein MD Partner, Managing Member & Founder Kearny Venture Partners
Campbell Murray MD Managing Director Novartis Venture Fund
Chau Khuong Private Equity Partner OrbiMed
Request full access to PitchBook